← All organizations
First clinical trial
Oct 1, 2006Last known activity
Jul 8, 2016
Defunct as of Dec 22, 2017
Timeline
2000s
- Jun 1, 2000
Arno Therapeutics— Founded
2010s
- Dec 22, 2017
Arno Therapeutics— Defunct
Drugs by trial phase (7 distinct, 9 trials)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Burkitt Lymphoma
- Carcinoma
- Carcinoma, Renal Cell
- Glioblastoma
- Gliosarcoma
- Hodgkin Disease
- Immunoblastic Lymphadenopathy
- Intraocular Lymphoma
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia, Prolymphocytic
- Leukemia, T-Cell
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Extranodal NK-T-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Lymphomatoid Granulomatosis
- Lymphoproliferative Disorders
- Multiple Myeloma
- Mycoses
- Mycosis Fungoides
- Myelodysplastic Syndromes
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Plasmablastic Lymphoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Prostatic Neoplasms
- Recurrence
- Sarcoma
- Sezary Syndrome
- Syndrome
- Waldenstrom Macroglobulinemia
Recent trials (9)
- NCT02795819CollaboratorPhase 1Jul 8, 2016
- NCT02049190Lead sponsorPhase 1/Phase 2Feb 1, 2014
- NCT02052128Lead sponsorPhase 1/Phase 2Jan 1, 2014
- NCT01202370CollaboratorPhase 1Sep 1, 2010
- NCT01129193CollaboratorPhase 1May 4, 2010
- NCT01124539Lead sponsorPhase 2Dec 1, 2009
- NCT00978523Lead sponsorPhase 1Aug 1, 2009
- NCT00956787Lead sponsorPhase 2Jun 1, 2009
- NCT00389480Lead sponsorPhase 1Oct 1, 2006
Details
- Founded
- Parsippany, NJ, US Jun 1, 2000
- Last known activity
- Jul 8, 2016